Skip to main content

A Revolutionary Approach to Treatment and Drug Delivery

Cellular Nanoparticle Platform Technology

About Cellics Therapeutics

Cellics Therapeutics leverages the multifaceted Cellular Nanoparticle (CNP) technology to develop nano-therapeutics and drive breakthrough drug delivery for mRNA, siRNA, proteins and small molecules. Cellics’ two dynamic nanoplatforms, Cellular Nanosponges and the Cellular Nanoparticle drug delivery technology, harness the power of cell membranes to craft specialized nanoparticle-based therapeutics. Derived from a variety of wild-type or engineered human cells, the CNP technology has the potential to address a broad range of diseases. Cellics is a privately held San Diego-based biopharmaceutical company founded by UC San Diego Professor Liangfang Zhang.

Cellular Nanosponge Platform

The Cellular Nanosponge platform includes a supportive nanoparticle core that is coated intact with wild-type or engineered cell membrane. The resulting nanostructure retains the surface protein receptors from the cell membrane, which mirrors innate cells, and can therefore serve as a decoy to bind and neutralize bacterial toxins, cytokines and viruses.

Cellular Nanoparticle Drug Delivery

Cellular Nanoparticles can facilitate targeted and intracellular delivery of mRNA, siRNA, proteins and small molecules. The platform allows for a high drug loading capacity, targeted drug delivery, intracellular delivery, and a potentially better safety profile.

Explore Cellular Nanoparticle Technology

Explore Cellular Nanoparticle Technology

Explore Cellular Nanoparticle Technology

Explore Cellular Nanoparticle Technology

Explore Cellular Nanoparticle Technology

Sign Up for Updates

Sign Up for Updates

Sign Up for Updates

Sign Up for Updates

Sign Up for Updates